Mary Jenkins | Senior Manager, IR |
Doug Ingram | President and CEO |
Ian Estepan | EVP and CFO |
Dallan Murray | SVP and Chief Customer Officer |
Dr. Louise Rodino-Klapac | EVP, Head of R&D and Chief Scientific Officer |
Gena Wang | Barclays |
Tazeen Ahmad | BofA |
Gil Blum | Needham & Company |
Colin Bristow | UBS |
Matthew Harrison | Morgan Stanley |
Brian Abrahams | RBC |
Brian Skorney | Baird |
Tim Lugo | William Blair |
Anupam Rama | JP Morgan |
Hartaj Singh | Oppenheimer |
Anvita Gupta | Cowen |
Yun Zhong | BTIG |
Zhiqiang Shu | Berenberg |
Gavin Clark-Gartner | Evercore ISI |
Good afternoon, and welcome to the Sarepta Therapeutics Third Quarter 2022 Earnings Call.
As a reminder, today’s program is being recorded. [Operator Instructions] At this time, I’ll turn the call over to Mary Jenkins, Senior Manager, Investor Relations. Please go ahead.
Thank you, Kathy, and thank you for joining today’s call.